Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

112 та иш

Иш: From cell cycle control to cancer therapy: exploring the role of CDK1 and CDK2 in tumorigenesis

  1. CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity

    Shigeaki Sunada, Hiroko Saito, Doudou Zhang +2

    Мақола20212 иқтибос
    ABI

  2. Molecular overlay-guided design of new CDK2 inhibitor thiazepinopurines: Synthesis, anticancer, and mechanistic investigations

    Ebtehal M. Husseiny, Hamada S. Abulkhair, Asmaa Saleh +3

    Мақола20232 иқтибос
    ABI

  3. LncRNA-DANCR: A valuable cancer related long non-coding RNA for human cancers

    Khaing Zar Thin, Xuefang Liu, Xiaobo Feng +2

    Шарҳ мақола20182 иқтибос
    ABI

  4. LncRNA PVT1 regulates growth, migration, and invasion of bladder cancer by miR‐31/<i>CDK1</i>

    Zhao‐ju Tian, Shuang Cao, Li Cheng +6

    Мақола20182 иқтибос
    ABI

  5. Long noncoding RNA FOXD2‐AS1 promotes glioma cell cycle progression and proliferation through the FOXD2‐AS1/miR‐31/CDK1 pathway

    Jin Wang, Bingqiang Li, Cunzu Wang +3

    Мақола20192 иқтибос
    ABI

  6. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance

    Silpa Narayanan, Chao‐Yun Cai, Yehuda G. Assaraf +6

    Шарҳ мақола20192 иқтибос
    ABI

  7. miR-155 Accelerates the Growth of Human Liver Cancer Cells by Activating CDK2 via Targeting H3F3A

    Xiaoru Xin, Yanan Lu, Sijie Xie +11

    Мақола20202 иқтибос
    ABI

  8. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer

    Xi Jin, Li‐Ping Ge, Da‐Qiang Li +4

    Мақола20202 иқтибос
    ABI

  9. Ketamine Induces Ferroptosis of Liver Cancer Cells by Targeting lncRNA PVT1/miR-214-3p/GPX4

    Guannan He, Naren two ya Bao, Shuang Wang +3

    Мақола20212 иқтибос
    ABI

  10. LncRNA PVT1 influences breast cancer cells glycolysis through sponging miR-145-5p

    Huan Qu, Xingxing Li, Fei Chen +5

    Мақола20232 иқтибос
    ABI

  11. Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding

    Erik B. Faber, Luxin Sun, Jian Tang +15

    Мақола20232 иқтибос
    ABI

  12. lncRNA PVT1 silencing inhibits gastric cancer cells’ progression via enhancing chemosensitivity to paclitaxel

    Bahar Naseri, Nader Farsad-Akhtar, Amirhossein Mardi +4

    Мақола20242 иқтибос
    ABI

  13. Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222

    Adam P. Dommer, Vishnu Kumarasamy, Jianxin Wang +6

    Мақола20252 иқтибос
    ABI

  14. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  15. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  16. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  17. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  18. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  19. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  20. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  21. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  22. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  23. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  24. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  25. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI